In a research report published Wednesday, Canaccord analyst reiterated a Buy rating on shares of Medivation Inc (NASDAQ:) with a price target of $70, after the drug maker reported mixed second quarter results and affirmed its guidance, sending shares slightly up Wednesday.
Newman noted, “On its call, Medivation announced Xtandi sales of ~$330M (missing $338M consensus slightly), but more important for the long-term growth story of the drug was the...
More